All In Biotech

Drug Trial Radar · NCT05556863

Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Oct 18, 2021

Primary completion

Nov 20, 2023

Study completion Nov 20, 2023

Sponsor

Lead sponsor
Electra Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Sep 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.

Conditions

  • Healthy Volunteers

Interventions

  • ELA026Drug

    Single dose of ELA026

  • ELA026Drug

    Multiple doses of ELA026

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability].Time frame: By week 3

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

  • Medical University of Vienna

    Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.